Science & Technology
Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44HL166018-01A1
Award Ceiling
$2.9M
Award Floor
$2.9M
Close Date
May 31, 2026
77 days leftTotal Funding
$2.9M
Expected Awards
1
Posted Date
Jun 15, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R44HL166018-01A1
Description
SBIR Phase Phase II award: "Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia" awarded to ReNeuroGen LLC in Elm Grove, Wisconsin. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,920,336. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.